首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Ifna11 |
| Uniprot No | Q61716 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-190aa |
| 氨基酸序列 | CDLPHTY NLRNKRALKV LAQMRRLSPL SCLKDRQDFG FPLEKVDAQQ IKKAQAIPVL RDLTQQILNL FTSKASSAAW NATLLDSFCN DLHQQLNDLQ GCLMQQVGVQ EPPLTQEDAL LAVRIYFHSI TVFLREKKHS PCAWEVVRAE VWRALSSSVN LLARLSEEKA |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Ifna11重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *Expression and functional characterization of recombinant murine interferon-alpha11*
**作者**: Yan H et al.
**摘要**: 该研究成功在大肠杆菌中表达并纯化重组小鼠Ifna11蛋白，证实其具有抗病毒活性，并通过STAT1磷酸化激活干扰素信号通路，提示其在免疫调节中的潜在作用。
2. **文献名称**: *Structural insights into human interferon-alpha11 subtype specificity*
**作者**: Li J, Wang Q.
**摘要**: 通过X射线晶体学解析人源Ifna11重组蛋白的三维结构，揭示其与受体IFNAR2结合的特异性位点，为设计靶向干扰素疗法提供结构基础。
3. **文献名称**: *IFNA11 recombinant protein enhances antiviral response in porcine macrophages*
**作者**: Chen L et al.
**摘要**: 研究发现猪源Ifna11重组蛋白可显著诱导巨噬细胞中ISG15等干扰素刺激基因的表达，并抑制猪繁殖与呼吸综合征病毒(PRRSV)的复制，表明其作为抗病毒治疗剂的潜力。
---
注：上述文献为示例，实际引用时需核实具体数据库(如PubMed、ScienceDirect)中的真实论文信息。
Interferon alpha-11 (IFNA11) is a member of the type I interferon (IFN) family, a group of cytokines critical in mediating innate immune responses against viral infections and modulating adaptive immunity. Discovered in the late 20th century, IFNA11 shares structural and functional similarities with other IFN-α subtypes, characterized by a conserved helical structure and binding to the common interferon-alpha/beta receptor (IFNAR). However, subtle sequence variations among subtypes, including IFNA11. contribute to differences in receptor affinity, signaling potency, and biological activity, enabling fine-tuned immune regulation.
Recombinant IFNA11 is produced using genetic engineering techniques, typically via expression in bacterial (e.g., *E. coli*) or mammalian cell systems. This allows large-scale production of the protein with high purity and consistency. The recombinant form retains the native protein’s ability to activate the JAK-STAT signaling pathway, inducing interferon-stimulated genes (ISGs) that drive antiviral, antiproliferative, and immunomodulatory effects. Its role in promoting MHC class I expression and enhancing dendritic cell maturation underscores its relevance in cancer immunotherapy and antiviral therapies.
Research on recombinant IFNA11 has gained attention due to its potential subtype-specific functions. For example, studies suggest it may exhibit distinct kinetics in antiviral activity or differential effects on certain cell types compared to other IFN-α subtypes. These properties make it a valuable tool for dissecting subtype-specific signaling mechanisms and developing targeted therapies. Additionally, recombinant IFNA11 is used in preclinical models to explore its efficacy against viruses like hepatitis B/C and cancers such as melanoma. Quality control during production ensures minimal endotoxin contamination and proper folding, validated through assays like SDS-PAGE, Western blot, and functional bioassays. Ongoing research aims to optimize its clinical applicability while balancing potency with reduced systemic toxicity.
×
